Home
Conditions
Carcinoma, Hepatocellular

Clinical trial condition

Carcinoma, Hepatocellular

Explore clinical trials studying Carcinoma, Hepatocellular. Study availability and eligibility vary by location and protocol.

2,099 public trials 530 recruiting studies

Refine in advanced search Browse all conditions

Carcinoma, Hepatocellular trial results

Recruiting

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

NCT05844046

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Hospital of the University of Munich Munich, Germany

Klinikum Rechts der Isar of the Technical University Munich Munich, Germany

Würzburg University Hospital Würzburg, Germany

View Trial Details

Recruiting

Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

NCT06498622

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: No.2 People's Hospital of Fuyang city Fuyang, Anhui, China

Anhui province hospital Hefei, Anhui, China

View Trial Details

Recruiting

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

NCT06492408

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
Locations: The Second Affiliated Hospital of Guangzhou Medical University Guanzhou, Guangdong, China

View Trial Details

Recruiting

TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

NCT06487663

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +13 more
Locations: Tianjin Medical University Cancer Institute and Hospital Tianjin, China

View Trial Details

Recruiting

Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)

NCT06090656

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Sun Yat-Sen University Cancer Center Guangzhou, Guangdong, China

View Trial Details

Recruiting

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

NCT06482801

Conditions: Adenocarcinoma, Antibody, Carcinoma, +10 more
Locations: Second Affiliated Hospital of Guangzhou Medical University Guangzhou, China

View Trial Details

Recruiting

Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib

NCT06478927

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Henan Cancer Hospital Zhengzhou, Henan, China

View Trial Details

Recruiting

Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors

NCT04952272

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +16 more
Locations: The Second Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China

View Trial Details

Recruiting

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

NCT03755739

Conditions: Adenocarcinoma, Adnexal Diseases, Breast Cancer, +65 more
Locations: The Second Affiliated Hospital of Guangzhou Medical University Guanzhou, Guangdong, China

View Trial Details

Recruiting

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

NCT04803318

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
Locations: The Second Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China

View Trial Details

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular trial results

Related conditions